FDA green-lights prostate imaging system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has cleared ProUroCare ProUroScan elasticity mechanical imaging system, which produces color images of men's prostate glands as an aid in detecting prostate abnormalities that were previously detected by digital rectal exam (DRE).

The ProUroScan system constructs color 2D and 3D maps of the prostate that, when in agreement with a DRE finding, can be stored in EHRs for future analysis and comparison. It features tactile elasticity imaging technology, which uses a handheld pressure-sensing rectal probe and image construction software to produce prostate maps, which is distinct from traditional ultrasound imaging, according to Minneapolis-based ProUroCare.